Dexamethasone-induced healing of chronic leg ulcers in a patient with defective organization of the extracellular matrix of fibronectin

British Journal of Dermatology

Volumn 142, Issue 1, 2000, Pages 166-170

  De Panfilis, G ^a   Ghidini, A ^a   Graifemberghi, S ^a   Barlati, S ^b   Zoppi, N ^b   Colombi, M ^b  

^a Azienda Spedali Civili ^*  (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Fibronectin; Leg ulcers; Wound healing

Indexed keywords

DEXAMETHASONE; FIBRONECTIN;

ADULT; ARTICLE; CASE REPORT; COLLAGEN SYNTHESIS; EXTRACELLULAR MATRIX; GENETIC ORGANIZATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOFLUORESCENCE; LEG ULCER; MALE; PRIORITY JOURNAL; RECEPTOR BINDING; SKIN FIBROBLAST; ULCER HEALING; WOUND HEALING;

ADULT; ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; FIBRONECTINS; HUMANS; LEG ULCER; MALE; WOUND HEALING;

EID: 0033968921     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03262.x     Document Type: Article

References (17)

1. Colvin RB. Fibronectin in wound healing. In: Fibronectin (Mosher DF, ed.). San Diego: Academic Press Inc, 1989: 213-54.
2. Quaglino DJ, Nanney LB, Kennedy R et al. Transforming growth factor-beta stimulates wound healing and modulates extracellular matrix gene expression in pig skin. I. Excisional wound model. Lab Invest 1990; 63: 307-19.
3. Oliver N, Babu M, Diegelmann R. Fibronectin gene transcription is enhanced in abnormal wound healing. J Invest Dermatol 1992; 99: 579-86.
4. Clark RA. Regulation of fibroplasia in cutaneous wound repair. Am J Med Sci 1993; 306: 42-8.
5. Steinmann B, Royce PM, Superti-Furga A. The Ehlers-Danlos syndrome. In: Connective Tissue and its Heritable Disorders Molecular, Genetic and Medical Aspects (Royce PM, Steinmann B, eds). New York: Wiley-Liss Inc, 1993: 351-407.
6. Barlati S, Moro L, Gardella R et al. Phenotypic correction of the defective fibronectin extracellular matrix of Ehlers-Danlos syndrome fibroblasts. Cell Biol Int Rep 1991; 15: 1183-94.
7. Byers PH. Ehlers-Danlos syndrome: recent advances and current understanding of the clinical and genetic heterogeneity. J Invest Dermatol 1994; 103 (Suppl.): 47-52S.
8. Moro L, Colombi M, Zoppi N et al. Correction of the defective extracellular matrix of Ehlers-Danlos syndrome skin fibroblasts by dexamethasone. Cell Biol Int Rep 1994; 18: 29-37.
9. Zoppi N, Ghinelli A, Gardella R et al. Effect of dexamethasone on the assembly of the matrix of fibronectin and on its receptors organization in Ehlers-Danlos skin fibroblasts. Cell Biol Int 1998; 22: 499-508.
10. Burton CS. Management of chronic and problem lower extremity wounds. Dermatol Clin 1993; 11: 767-73.
11. Burton CS. Treatment of leg ulcers. Dermatol Clin 1993; 11: 315-23.
12. Ohlsson P, Larsson K, Lindholm C et al. A cost-effectiveness study of leg ulcer treatment in primary care. Comparison of saline- gauze and hydrocolloid treatment in a prospective, randomized study. Scand J Prim Health Care 1994; 12: 295-9.
13. Kupperwasser B. Evaluation de la qualité des soins en anesthésie. Ann Fr Anesth Réanim 1996; 15: 57-70.
14. Ignotz RA, Massaguè J. Type β transforming growth factor controls the adipogenic differentiation of 3T3 fibroblasts. Proc Nat Acad Sci USA 1985; 82: 8530-4.
15. Beighton P, De Paepe A, Hall JG et al. Molecular nosology of heritable disorders of connective tissue. Am J Med Genet 1992; 42: 431-48.
16. Brauchle M, Fässler R, Werner S. Suppression of keratinocyte growth factor expression by glucocorticoids in vitro and during wound healing. J Invest Dermatol 1995; 105: 579-84.
17. Kähäri VM, Häkkinen L, Westermack J et al. Differential regulation of decorin and biglycan gene expression by dexamethasone and retinoic acid in cultured human skin fibroblasts. J Invest Dermatol 1995; 104: 503-8.